Hengrui Pharmaceutical announced that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received the SHR-4595 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials of the drug in patients with advanced solid tumors in the near future. SHR-4595 for injection is a therapeutic biological product independently developed by the company. It is intended to treat advanced malignant solid tumors. Up to now, related projects have invested about 16.4 million yuan in R&D. The drug still needs to complete clinical trials and pass review and approval before it can be marketed. There is uncertainty.

Hengrui Pharmaceutical announced that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received the SHR-4595 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials of the drug in patients with advanced solid tumors in the near future. SHR-4595 for injection is a therapeutic biological product independently developed by the company. It is intended to treat advanced malignant solid tumors. Up to now, related projects have invested about 16.4 million yuan in R&D. The drug still needs to complete clinical trials and pass review and approval before it can be marketed. There is uncertainty.